GSK's triple drug cuts flare-ups in chronic lung disease

LONDON (Reuters) - An experimental three-in-one inhaled drug from GlaxoSmithKline significantly cut flare-ups in patients with chronic lung disease in a clinical trial, researchers said on Tuesday.